Hormonal Therapy in Advanced or Recurrent Endometrial Cancer with Brian Slomovitz

 In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Brian Slomovitz to discuss hormonal therapy in advanced or recurrent endometrial cancer. Dr. Slomovitz is a Gynecologic Oncologist at Mount Sinai Medical Center in Miami Beach, Florida, and Professor of Obstetrics and Gynecology at the Wertheim College of Medicine at Florida International University. He is an internationally recognized leader in gynecologic oncology clinical trials, specifically in immunotherapy and novel biomarker therapeutics. He also is a leader in sentinel lymph node detection for gynecologic malignancies.

Highlights:

While current recommendations include chemotherapy as first-line treatment for metastatic or recurrent endometrial cancer, emerging evidence suggests that hormonal therapy, particularly in combination with other treatment regimens guided by biomarkers, could be efficacious in selected subtypes (low-grade endometrioid carcinoma of the endometrium).

Hormonal therapy offers many benefits, including oral dosing and fewer side effects.

If there is progression after hormonal therapy, patients would still be eligible for other trials, and use of hormonal therapy does not preclude the use or limit the benefits of future chemotherapy.